NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

Search Plan my trip
NASDAQ / LIVE COMPANY INTELLIGENCE

Aclaris Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERACRS
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ACRS COVERAGE

What’s moving Aclaris Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight

Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight

The development tests whether Aclaris Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
Aclaris Therapeutics, Inc. Added to Russell 3000 and Russell 2000 Indexes Following 2025 Annual Reconstitution

Aclaris Therapeutics, Inc. Added to Russell 3000 and Russell 2000 Indexes Following 2025 Annual Reconstitution

The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Investors are testing whether Aclaris Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ACRS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-06 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-06 · Period 2026-08-06SEC ↗8-KMaterial company eventFiled 2026-08-06 · Period 2026-08-06SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-06-04SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-23 · Period 2026-06-04SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-09-21SEC ↗
EARNINGS / QUARTERLY TRACKER

Aclaris Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.